This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TissueTech | |
|---|---|
| Name | TissueTech |
| Type | Private |
| Founded | 2002 |
| Founder | Stephen R. Herbert |
| Headquarters | Miami, Florida |
| Industry | Biotechnology |
| Products | Amniotic membrane products, ophthalmic biologics, wound care biologics |
TissueTech is a biotechnology company specializing in the development, manufacturing, and commercialization of human placental and amniotic membrane–derived biologic products for ophthalmic, dermatologic, and surgical indications. Founded in the early 21st century, the organization integrates aspects of regenerative medicine, tissue banking, and medical device commercialization to supply hospitals, clinics, and research institutions across the United States and internationally.
TissueTech was established in 2002 during a period of expanding interest in regenerative medicine alongside institutions such as Massachusetts General Hospital, Johns Hopkins Hospital, Mayo Clinic, and academic centers including Harvard Medical School and Stanford University School of Medicine. Early work paralleled developments in amniotic membrane research at facilities like Basel University Hospital and collaborations with tissue banking standards influenced by organizations such as the American Association of Tissue Banks and regulatory frameworks exemplified by the United States Food and Drug Administration. In its formative years, TissueTech pursued donor sourcing and processing technologies inspired by techniques documented in publications from The New England Journal of Medicine and The Lancet, positioning itself amid competitors including BioTissue, Amniox Medical, and MiMedx Group.
Throughout the 2000s and 2010s, TissueTech expanded its manufacturing capabilities and intellectual property portfolio, filing patents concurrent with peers at companies like Organogenesis and engaging clinical investigators affiliated with Bascom Palmer Eye Institute and Wills Eye Hospital. The company’s trajectory reflects broader commercialization trends observed in biotechnology markets tracked by entities such as S&P Global, Nasdaq, and Bloomberg.
TissueTech operates as a privately held company headquartered in Miami, Florida with corporate governance influenced by executive leadership and a board of directors. Financial and ownership details have involved private investors, venture capital groups comparable to firms like Sequoia Capital, New Enterprise Associates, and strategic partners found in the health sector such as Baxter International and Becton, Dickinson and Company—though specific stakeholdings vary over time. Its corporate structure comprises research and development, regulatory affairs, quality control, manufacturing, and commercial divisions modeled similarly to organizational frameworks at Thermo Fisher Scientific and GE Healthcare. Strategic decisions have at times been informed by advisory relationships with clinicians from institutions like Mount Sinai Health System and Cleveland Clinic.
The company’s principal offerings center on cryopreserved and dehydrated amniotic membrane products formulated for wound healing and ocular surface reconstruction. These products are developed using proprietary processing methods intended to preserve extracellular matrix components, growth factors, and anti-inflammatory proteins, paralleling scientific efforts reported by researchers at Stanford University, University of California, San Francisco, and Johns Hopkins University. Product examples include ophthalmic allografts used in pterygium surgery and persistent epithelial defect management, with functional analogs found in the portfolios of Ocular Therapeutix and Stryker Corporation. Manufacturing emphasizes tissue sourcing, aseptic processing, preservation technologies akin to systems from CryoLife and packaging standards comparable to Medtronic.
Clinical applications span ophthalmology, wound care, and surgical adjuncts. In ophthalmology, products are applied for corneal ulceration, conjunctival reconstruction, and ocular surface disease, supporting procedures performed at tertiary centers such as Bascom Palmer Eye Institute and Wills Eye Hospital. Wound care uses include chronic ulcers, diabetic foot ulcers, and burn management, topics extensively investigated in trials listed in registries maintained by ClinicalTrials.gov and reported in journals like Ophthalmology and Journal of Wound Care. Collaborative clinical research initiatives have engaged principal investigators from University of Miami Miller School of Medicine, University of Pennsylvania Perelman School of Medicine, and international groups at King's College London.
Regulatory oversight involves compliance with standards set by the United States Food and Drug Administration, tissue banking guidance from the American Association of Tissue Banks, and quality frameworks similar to ISO 13485 for medical devices. Product marketing has required submissions and interactions with the FDA’s Center for Biologics Evaluation and Research and adherence to Good Tissue Practice regulations. Quality control programs implement sterilization validation, donor screening aligned with protocols from the American Red Cross and infectious disease testing guided by agencies such as the Centers for Disease Control and Prevention.
TissueTech has pursued collaborations with academic medical centers, contract research organizations like Parexel and PPD, Inc., and supply-chain partners in logistics and distribution analogous to relationships maintained by Cardinal Health and McKesson Corporation. Academic collaborations have involved investigators from Mount Sinai Health System, University of California, Los Angeles, and international hospitals in Europe and Asia, facilitating multi-center studies and product adoption in specialist clinics.
Like several peers in the tissue-derived biologics sector, the company has faced legal and regulatory scrutiny concerning labeling, marketing claims, and patent disputes. Comparable litigation in the industry has involved entities such as MiMedx Group and NuVasive with cases adjudicated in federal courts including the United States District Court for the Southern District of Florida and appeals considered by the United States Court of Appeals for the Eleventh Circuit. Controversies in the sector more broadly have touched on donor consent practices, reimbursement disputes with payers like Centers for Medicare & Medicaid Services, and enforcement actions overseen by the Department of Justice and state attorneys general.
Category:Biotechnology companies